TYMS and non-small cell lung carcinoma: In view of the potential utility that a clinical TS inhibitor imaging assay will provide the research community, we conducted a detailed lesion assessment of 18F-FLT flares to investigate whether the TS inhibitor pharmacodynamic imaging technique is a reliable early predictor of treatment response and survival in NSCLC patients scheduled for treatment with pemetrexed ± platinum, using the timing informed by our preclinical studies [14] and initial clinical studies [16].